Skip to main content
Clinical Trials/NCT04741334
NCT04741334
Completed
Not Applicable

Mild Head Injury and Oral Anticoagulants: a Prospective Observational Study

Fondazione Policlinico Universitario Agostino Gemelli IRCCS1 site in 1 country2,127 target enrollmentSeptember 27, 2019

Overview

Phase
Not Applicable
Intervention
direct anticoagulant
Conditions
Craniocerebral Trauma
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrollment
2127
Locations
1
Primary Endpoint
Hospital admission
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Approximately 20% of patients with mild head injury presenting to the Emergency Department (ED) is taking antiplatelet agents and 10% is taking oral anticoagulants. The aim of the study is to determine the prevalence of cerebral hemorrhage in patients presenting to the ED with an MHI. It also aims to determine whether the use of antiplatelet agents and anticoagulants may be a risk factor for the occurrence of cerebral hemorrhage and mortality. This is a prospective observational study that will include all patients who present to ED at Gemelli Hospital for an MHI for 2 years. Patients will be divided into four groups according to whether or not they are taking anticoagulants and antiplatelet drugs. Groups will be compared to evaluate the possible increased risk of complications in patients on treatment and among the different medications.

Detailed Description

Mild head injury (MHI) is one of the most common causes of emergency department (ED) admission. Approximately 20% of MHI patients admitted to PS with a mild traumatic brain injury is taking antiplatelet medications and 10% is taking oral anticoagulants. There are a few data describing the risk of adverse events in patients with MHI taking direct oral anticoagulants (DOAC), and they are of poor quality. The aim of this study is to investigate the prevalence of cerebral hemorrhage in patients presenting to the ED with an MHI. Moreover, it will be evaluated whether the use of antiplatelet agents and anticoagulants may be a risk factor for the occurrence of cerebral hemorrhage and mortality. This is a prospective observational study that will include all patients who present to the ED at Gemelli Hospital for an MHI for 2 years. Patients will be divided into four groups according to whether or not they are taking anticoagulants and antiplatelet agents. The investigators will then determine the prevalence of cerebral hemorrhage, the need for hospitalization or neurosurgery, and mortality at different follow-up time points for each group. The investigators will compare the groups to assess the potential increased risk in patients on treatment and among drugs. It can be hypothesized that the use of dicumarol anticoagulants and antiplatelet agents for head injury is associated with a higher risk of cerebral hemorrhage than the use of DOACs. It may be, also, hypothesize that patients taking DOACs are at a higher risk of bleeding than patients not treated with antiplatelet/anticoagulant agents.

Registry
clinicaltrials.gov
Start Date
September 27, 2019
End Date
January 31, 2022
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

CANDELLI MARCELLO

Adjunct Professor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Eligibility Criteria

Inclusion Criteria

  • Patients presenting with head trauma within 6 hours from the trauma w
  • Age\> 17 years
  • Glasgow Coma Scale (GCS) \> 13

Exclusion Criteria

  • Presence of serious diseases with a potentially less than one-month prognosis (patient with trauma following syncope from severe cardiovascular disease such as pulmonary embolism, myocardial infarction, ventricular arrhythmias, aortic dissection, aortic aneurysm rupture)
  • Severe trauma in other body areas (identified in the Emergency department by means of CT scan of other body areas such as chest CT, abdomen CT, total body CT).
  • history of congenital or acquired coagulation disorders (Haemophiliacs, patients with severe liver cirrhosis)
  • Patients undergoing dual antiplatelets drugs or combination therapy of antiplatelet and anticoagulant
  • Patients presenting with a GCS\>13 and with focal neurologic deficits, suspected sunken fracture, or clinical signs of skull base fracture

Arms & Interventions

patients in therapy with direct anticoagulant

Patients presenting in ED with mild head trauma and in therapy with direct anticoagulants

Intervention: direct anticoagulant

patients in therapy with oral anticoagulant (dicumarolics)

Patients presenting in ED with mild head trauma and in therapy with oral anticoagulants (dicumarols)

Intervention: Dicumarols

patients in therapy with antiplatelet drugs

Patients presenting in ED with mild head trauma and in therapy with antiplatelets

Intervention: antiplatelet drugs

Outcomes

Primary Outcomes

Hospital admission

Time Frame: 48 hours

Number of participants with hospital admission for head trauma complication

early Cerebral hemorrhage

Time Frame: 24 hours

Number of participants with evidence of cerebral hemorrhage at head CT scan

skull fracture

Time Frame: 24 hours

Number of participants with evidence of skull fracture at head CT scan

Secondary Outcomes

  • late mortality(30 days)
  • early mortality(24 hours)
  • late cerebral hemorrhage(30 days)

Study Sites (1)

Loading locations...

Similar Trials